Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Silence Therapeutics (SLN) Cash from Financing Activities: 2018-2024

Historic Cash from Financing Activities for Silence Therapeutics (SLN) over the last 7 years, with Dec 2024 value amounting to $142.1 million.

  • Silence Therapeutics' Cash from Financing Activities fell 99.92% to $1,000 in Q2 2025 from the same period last year, while for Jun 2025 it was $7.9 million, marking a year-over-year decrease of 95.12%. This contributed to the annual value of $142.1 million for FY2024, which is 344.90% up from last year.
  • Latest data reveals that Silence Therapeutics reported Cash from Financing Activities of $142.1 million as of FY2024, which was up 344.90% from $31.9 million recorded in FY2023.
  • Silence Therapeutics' Cash from Financing Activities' 5-year high stood at $142.1 million during FY2024, with a 5-year trough of $19.8 million in FY2020.
  • In the last 3 years, Silence Therapeutics' Cash from Financing Activities had a median value of $52.6 million in 2022 and averaged $75.5 million.
  • Its Cash from Financing Activities has fluctuated over the past 5 years, first plummeted by 39.26% in 2023, then spiked by 344.90% in 2024.
  • Silence Therapeutics' Cash from Financing Activities (Yearly) stood at $19.8 million in 2020, then skyrocketed by 113.28% to $42.3 million in 2021, then grew by 24.44% to $52.6 million in 2022, then slumped by 39.26% to $31.9 million in 2023, then spiked by 344.90% to $142.1 million in 2024.